Johnson & Johnson 2022 annual meeting is on April 28, 2022, at 7:00 am Pacific. It is a virtual-only meeting on the Broadridge platform. Of course, I recommend voting in advance, especially since they have made it very difficult to vote at the meeting and maybe even to enter the meeting. To enhance corporate governance and long-term value, vote Against Scott Davis, Ian Davis, Gorsky, Hewson, Joly, Washington, pay, incentive plan, auditor, #6, #11. Vote FOR all other proposals.
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. Below, is how I voted and why in a much shorter format than I’ve used in prior years since I am pressed for time.
Johnson & Johnson 2022: ISS Rating
From the Yahoo Finance profile page: Johnson & Johnson’s ISS Governance QualityScore as of April 1, 2022 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 4; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Johnson & Johnson 2022: CorpGov Recommendations
|Item||Egan-Jones Recommendation||CorpGov.net Recommendation|
|1A – 1N – Election of Directors||FOR, EXCEPT D. Scott Davis, Ian E. L. Davis, Alex Gorsky, Marillyn A. Hewson, Hubert Joly, and A. Eugene Washington, M.D., M.Sc.||FOR, EXCEPT D. Scott Davis, Ian E. L. Davis, Alex Gorsky, Marillyn A. Hewson, Hubert Joly, and A. Eugene Washington, M.D., M.Sc.|
|2 – Advisory Vote to Approve Executive Compensation||FOR||AGAINST|
|3 – Approval of the 2022 Long-Term Incentive Plan (the “2022 Plan”)||AGAINST||AGAINST|
|4 – Ratification of the Appointment of Independent Auditors||AGAINST||AGAINST|
|5 – Shareholder Proposal – Federal Securities Laws Mandatory Arbitration Bylaw||AGAINST||ABSTAIN (withdrawn)|
|6 – Shareholder Proposal – Civil Rights, Equity, Diversity & Inclusion Audit Proposal||FOR||AGAINST|
|7 – Shareholder Proposal – Third Party Racial Justice Audit||FOR||FOR|
|8 – Shareholder Proposal – Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics||AGAINST||FOR|
|9 – Shareholder Proposal – Report on Public Health Costs of Protecting Vaccine Technology||AGAINST||FOR|
|10 – Shareholder Proposal – Discontinue Global Sales of Baby Powder Containing Talc||AGAINST||FOR|
|11 – Shareholder Proposal – Request for Charitable Donations Disclosure||AGAINST||AGAINST|
|12 – Shareholder Proposal – Third Party Review and Report on Lobbying Activities Alignment with Position on Universal Health Coverage||AGAINST||FOR|
|13 – Shareholder Proposal – Adopt Policy to Include Legal and Compliance Costs in Incentive Compensation Metrics||FOR||FOR|
|14 – Shareholder Proposal – CEO Compensation to Weigh Workforce Pay and Ownership||FOR||FOR|
Johnson & Johnson 2022: Management Proposals
Johnson & Johnson 2022: Shareholder Proposals
Proposal #5 was withdrawn. Proposal #6 is sponsored by the right-wing National Center for Public Policy (NCPPR). Although the title sounds positive, the actual language is concerned about discrimination against employees deemed “non-diverse.” I doubt that problem is rampant, so voted against it as a waste of money. Similarly #11 is sponsored by National Legal and Policy Center, another right-wing organization, although not as deceptive as (NCPPR). I would support reporting all donations of $5,000 and above to Section 501(c)(3) nonprofits and all donations to dark money 501(c)(4) political campaigns.
I am not going through most of the shareholder proposals but will refer the reader to exempt solicitations filed on most of them by fellow members of ICCR.
Johnson & Johnson 2022: Item #14: CEO Compensation to Weigh Workforce Pay and Ownership
This proposal from my wife, written by me, simply asks the Board to consider pay and stock ownership incentives of US Company employees when setting targets for CEO compensation. Bank of America, Bristol-Meyers Squibb, and several others this year have embraced this approach.
JNJ explains how it compares pay against peer companies in the proxy and argues it “already contemplates workforce compensation information” when setting CEO pay. They just don’t want to explain how in the proxy.
If we are to continue to groom CEO candidates from inside the Company, shouldn’t JNJ discuss pay and stock ownership in the context of its internal employees, as well as outside competitors?
Context may be helpful when considering your vote. Former CEO, Alex Gorsky was paid $30M last year. $16M in excess pay, according to HIP Investor’s regression analysis, comparing CEO pay to performance. 43% of shares voted against pay last year. That’s a record matched only by 32 of the S&P 500. And CEO pay at JNJ was 365 x median employee pay. Higher than at most companies. See The Most Overpaid CEOs.
There’s a strong correlation between overpaid CEOs and underperforming companies. Promoting from within is associated with higher performance.
Since our Company “already contemplates workforce compensation information” when setting CEO pay, why not just tell us how that is done?
I was delighted to see E-J recommend FOR: “Pay disparities in companies, in our view, could bring operational risks and reputational damage that is detrimental to shareholder value,” with similar comments in support by Trillium.
Vote FOR Proposal #14. CEO Compensation and Employee Compensation should be aligned. Describe that alignment in the proxy.
Lookup a few funds in our Shareowner Action Handbook to see how several funds have voted. I will be on the road but you can check back 5 days before the meeting. Several will have disclosed by then.
Johnson & Johnson 2022: Issues for Future Proposals
Looking at insightia for anti-shareholder provisions:
- No requirement for an independent Chair
- The special meeting threshold is high at 25%
- Proxy access is limited to groups of 20
Johnson & Johnson 2022: Mark Your Calendar
To be included in our Proxy Statement and Proxy Card for the 2023 Annual Meeting of Shareholders Due:November 16, 2022 Must comply with Rule 14a-8 under the U.S. Securities and Exchange Act of 1934, as amendedMust include the information specified under our By-Laws